Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

13
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
13
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

17
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
17
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

19
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
19
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.

BMJ open·2026
Same author

Clinical implications of the new definition of obesity among persons with HIV.

AIDS (London, England)·2026
Same author

Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.

The lancet. HIV·2026
Same author

Proteomic Profile After Intervention With Eplerenone Among Persons With HIV.

Open forum infectious diseases·2026
Same author

Perspectives on Research Participation Among Midlife Persons Living With HIV in the United States: A Survey Study.

The Journal of the Association of Nurses in AIDS Care : JANAC·2026
Same author

Molecular insights in HIV-associated cardiac dysfunction.

Communications medicine·2025

Related Experiment Video

Updated: Jul 12, 2025

Isolation, Transfection, and Culture of Primary Human Monocytes
09:13

Isolation, Transfection, and Culture of Primary Human Monocytes

Published on: December 16, 2019

13.5K

Large lessons learned from small vessels: coronary microvascular dysfunction in HIV.

Teressa S Thomas1, Allie R Walpert, Suman Srinivasa

  • 1Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Current Opinion in Infectious Diseases
|October 27, 2023
PubMed
Summary

Coronary microvascular dysfunction (CMD) is common in people with HIV (PWH), increasing heart failure risk. This condition affects PWH even with well-managed HIV and may be worse in women.

More Related Videos

Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation
10:04

Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation

Published on: January 12, 2016

9.3K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

Related Experiment Videos

Last Updated: Jul 12, 2025

Isolation, Transfection, and Culture of Primary Human Monocytes
09:13

Isolation, Transfection, and Culture of Primary Human Monocytes

Published on: December 16, 2019

13.5K
Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation
10:04

Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation

Published on: January 12, 2016

9.3K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Vascular Biology

Background:

  • Heart failure risk is elevated in people with HIV (PWH).
  • Early research focused on large vessel disease in HIV, but recent studies highlight small vessel disease, or coronary microvascular dysfunction (CMD).
  • CMD is a significant risk factor for heart failure and cardiovascular mortality, often occurring without significant atherosclerotic disease.

Approach:

  • This review synthesizes current understanding of CMD in the context of HIV.
  • It examines the role of inflammation and endothelial dysfunction in CMD pathogenesis.
  • Clinical studies and implications for PWH are discussed.

Key Points:

  • CMD is increasingly recognized in PWH, contributing to heart failure.
  • Inflammation and endothelial dysfunction are potential drivers of CMD in HIV.
  • CMD may worsen with antiretroviral therapy (ART) initiation but is also present in well-treated PWH.
  • Myocardial flow reserve (MFR), a marker for CMD, is reduced in PWH, similar to individuals with diabetes.
  • Women with HIV may experience more severe CMD than men.

Conclusions:

  • Alterations in the coronary microvasculature are a key factor in subclinical myocardial dysfunction among PWH.
  • CMD warrants further clinical investigation in PWH, particularly those without diagnosed cardiovascular disease.